Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications

Purpose of Review In this review, we discuss modern cytokine delivery systems in oncologic care, focusing on modalities being developed in the clinical trials or currently in use. These include pegylation, immune-cytokine drug conjugates, cytokine-expressing plasmid nanoparticles, nonviral cytokine...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2022-04, Vol.24 (4), p.389-397
Main Authors: Dholakia, Jhalak, Cohen, Alexander C., Leath, Charles A., Evans, Elizabeth T., Alvarez, Ronald D., Thaker, Premal H.
Format: Article
Language:English
Subjects:
Antitumor activity
Cancer immunotherapy
Clinical trials
Cytokines
Cytokines - therapeutic use
Humans
Immune system
Immuno-oncology (RM Bukowski and JH Finke
Immunologic Factors
Immunotherapy
Immunotherapy - adverse effects
Medicine
Medicine & Public Health
Nanoparticles
Neoplasms - pathology
Oncology
Section Editors
Topical Collection on Immuno-oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of Review In this review, we discuss modern cytokine delivery systems in oncologic care, focusing on modalities being developed in the clinical trials or currently in use. These include pegylation, immune-cytokine drug conjugates, cytokine-expressing plasmid nanoparticles, nonviral cytokine nanoparticles, viral systems, and AcTakines. Recent Findings Cytokine therapy has the potential to contribute to cancer treatment options by modulating the immune system towards an improved antitumor response and has shown promise both independently and in combination with other immunotherapy agents. Despite promising preliminary studies, systemic toxicities and challenges with administration have limited the impact of unmodified cytokine therapy. In the last decade, novel delivery systems have been developed to address these challenges and facilitate cytokine-based oncologic treatments. Summary Novel delivery systems provide potential solutions to decrease dose-limiting side effects, facilitate administration, and increase the therapeutic activity of cytokine treatments in oncology care. The expanding clinical and translational research in these systems provides an opportunity to augment the armamentarium of immune oncology and may represent the next frontier of cytokine-based immuno-oncology.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-022-01221-3